Literature DB >> 20673198

Medical and cost burden of atherosclerosis among patients treated in routine clinical practice.

Robert L Ohsfeldt1, Sanjay K Gandhi, Kathleen M Fox, Michael F Bullano, Michael Davidson.   

Abstract

OBJECTIVE: This investigation estimated medical costs attributable to treatment of patients diagnosed with atherosclerosis in routine US clinical practice.
METHODS: Using Medstat MarketScan claims data, direct costs of care and rates of cardiovascular (CV) events (i.e., myocardial infarction, stroke, revascularization) were examined for patients≥18 years of age with and without a diagnostic code for atherosclerosis from 1/1/2002 through 12/31/2004. Patients with an atherosclerosis ICD-9 code who had no history of CV events in the preceding 12 months (n=75,469) were evaluated. A comparison cohort (n=238,702) was matched on age, gender, geographic region, enrollment time period, and Charlson comorbidity index to estimate incremental costs attributable to atherosclerosis. Differences between patient groups were tested for CV event rates per 1,000 patients and monthly costs for 6 and 12 months before and after diagnosis.
RESULTS: Patients had a mean age of 58 years, 52% men, and a comorbidity index of 0.49. Patients diagnosed with atherosclerosis had significantly higher (p<0.001) rates of CV events (240/1000) after diagnosis, compared with patients without atherosclerosis (32/1000). Mean direct cost of care for patients diagnosed with atherosclerosis was $579/month for 12 months before and $1,074/month for 12 months after diagnosis, an 85% increase. Change in mean annual costs pre/post-index date was $5,232 ($436/month) higher among patients with than those without atherosclerosis (p<0.001). LIMITATIONS: The study population was restricted to patients with diagnosed clinical atherosclerosis based on specific ICD-9 codes. Matching of the patient cohorts was based on observed characteristics and other unobserved differences may exist.
CONCLUSIONS: Patients with diagnosed atherosclerosis incur significant clinical and economic burden, indicating a need for earlier diagnosis and treatment of atherosclerosis to help in reducing this burden.

Entities:  

Mesh:

Year:  2010        PMID: 20673198     DOI: 10.3111/13696998.2010.506348

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  8 in total

1.  Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome.

Authors:  Ekwutosi M Okoroh; Sheree L Boulet; Mary G George; W Craig Hooper
Journal:  Thromb Res       Date:  2015-10-17       Impact factor: 3.944

2.  OSA and atherosclerosis.

Authors:  Macy Mei-Sze Lui; Mary Sau-Man
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

3.  Impaired macrophage trafficking and increased helper T-cell recruitment with loss of cadherin-11 in atherosclerotic immune response.

Authors:  Camryn L Johnson; Lance Riley; Matthew Bersi; MacRae F Linton; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-09-10       Impact factor: 5.125

4.  Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.

Authors:  Mark D Danese; Michelle Gleeson; Lucie Kutikova; Robert I Griffiths; Ali Azough; Kamlesh Khunti; Sreenivasa Rao Kondapally Seshasai; Kausik K Ray
Journal:  BMJ Open       Date:  2016-08-05       Impact factor: 2.692

5.  Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.

Authors:  S Hallberg; S R Gandra; K M Fox; J Mesterton; J Banefelt; G Johansson; L-Å Levin; P Sobocki
Journal:  Eur J Health Econ       Date:  2015-06-16

6.  Management of sacroiliac joint disruption and degenerative sacroiliitis with nonoperative care is medical resource-intensive and costly in a United States commercial payer population.

Authors:  Stacey J Ackerman; David W Polly; Tyler Knight; Tim Holt; John Cummings
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-11

7.  Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study.

Authors:  Kathleen M Fox; Li Wang; Shravanthi R Gandra; Ruben G W Quek; Lu Li; Onur Baser
Journal:  BMC Cardiovasc Disord       Date:  2016-01-14       Impact factor: 2.298

8.  Linking In Vitro Models of Endothelial Dysfunction with Cell Senescence.

Authors:  Francisco R Jimenez Trinidad; Marta Arrieta Ruiz; Núria Solanes Batlló; Àngela Vea Badenes; Joaquim Bobi Gibert; Antoni Valera Cañellas; Mercè Roqué Moreno; Xavier Freixa Rofastes; Manel Sabaté Tenas; Ana Paula Dantas; Olga Tura-Ceide; Montserrat Rigol Muxart
Journal:  Life (Basel)       Date:  2021-11-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.